Status
Conditions
Treatments
About
This study evaluates the clinical effectiveness of platelet-rich plasma (PRP) injections compared with a home-based exercise program in patients with partial-thickness tears of the supraspinatus tendon. Partial supraspinatus tears are a common cause of chronic shoulder pain and functional limitation. PRP has been proposed as a biological treatment that may promote tissue healing, while therapeutic exercise remains a standard conservative intervention.
This prospective, controlled study includes two parallel groups. The PRP group receives three monthly ultrasound-guided intratendinous PRP injections, preceded by local anesthesia. The control group follows a structured home-based exercise program for the same overall treatment period. All participants are assessed at baseline and again two months after completing their assigned intervention.
The primary outcome is shoulder pain measured with a Visual Analog Scale (VAS). Secondary outcomes include shoulder range of motion (flexion, extension, abduction, adduction, internal and external rotation) and functional disability measured with the Constant-Murley Score. The study also analyzes whether patient characteristics such as age or sex are associated with clinical improvement.
The aim of this research is to compare two commonly used conservative treatment strategies and provide evidence to guide clinical decision-making for patients with partial-thickness supraspinatus tears.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Shoulder pain for more than 6 months with a Visual Analog Scale (VAS) score > 4.
Partial-thickness tear of the supraspinatus tendon confirmed by ultrasound.
No improvement in VAS after conservative treatment with NSAIDs and/or physical therapy during the previous 6 months.
Willingness to undergo blood extraction and PRP infiltrations as required by the protocol.
Exclusion criteria
Full-thickness tear of the supraspinatus tendon.
Active infection (osteomyelitis, septic arthritis).
Current treatment with NSAIDs, antiplatelet agents, or systemic immunosuppressants.
Severe thrombocytopenia.
Positive serology (syphilis, HIV, HBV, HCV).
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal